Suspected non-AD pathology in mild cognitive impairment

We aim to better characterize Mild Cognitive Impairment (MCI) patients with suspected non-Alzheimer’s Disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid and neuroimaging profile. MCI participants (n=361) from ADNI-GO/2 were designated ‘amyloid positive’ with abnormal Aβ42 levels (AMY+) and ‘neurodegeneration positive’ (NEU+) with abnormal hippocampal volume or hypometabolism using FDG-PET. SNAP was compared with the other MCI groups and with AMY− controls. AMY−NEU+/SNAP, 16.6%, were older than the NEU− groups, but not AMY− controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP MCI participants had similar Aβ42 levels, florbetapir and tau levels, but larger white matter hyperintensity volumes than AMY− controls and AMY−NEU− MCI participants. SNAP participants performed worse on all memory domains and on other cognitive domains, than AMY−NEU− participants, but less so than AMY+NEU+ participants. Subthreshold levels of cerebral amyloidosis are unlikely to play a role in SNAP MCI, but pathologies involving the hippocampus and cerebrovascular disease may underlie the neurodegeneration and cognitive impairment in this group.